StockData
Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc. (ARQT) shareholders

ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30397% above fair value
$27.33+0.18 (+0.66%)

Close on Nov 17, 2026Market cap $3.44BP/E 124.2Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
131M of 126M shares
Institutional holders
272
42 new, 36 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 68 sales
Net sold $13.95M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
BlackRock, Inc.17,751,43514.10%13G (passive) amendmentSep 30, 2026
Aaron Cowen
Joint filing with Suvretta Capital Management, LLC (9.99%), Averill Master Fund, Ltd. (9.10%)
9,534,8379.99%13G (passive) amendmentDec 31, 2023
Patrick J. Heron
Joint filing with James N. Topper (7.40%), Fhm Life Sciences Viii, L.L.C. (7.40%) and 2 more
8,943,7127.50%13D (active) amendmentAug 18, 2025
Rubric Capital Management LP
Joint filing with David Rosen (6.75%)
8,271,5776.75%13G (passive) amendmentDec 31, 2025
State Street Corporation7,718,6286.10%13G (passive)Sep 30, 2026
Polar Capital Holdings Plc
Joint filing with Polar Capital LLP (5.65%), Polar Capital Funds PLC - Biotechnology Fund (5.06%)
6,706,4755.65%13G (passive) amendmentMar 31, 2025
Polar Capital LLP
Joint filing with Polar Capital Holdings Plc (5.28%)
6,606,9455.28%13G (passive)Jun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ARQTValueChange% of portfolio
Suvretta Capital Management, LLC12,437,0009.89%$326.10M+110,0005.96%
BlackRock, Inc.10,545,4668.39%$276.50M+1,345,0550.00%
Frazier Life Sciences Management, L.P.9,874,5117.86%$258.91M–5.64%
Rubric Capital Management LP8,271,5776.58%$216.88M–1.99%
Polar Capital Holdings Plc6,606,9455.26%$173.23M+940,0050.41%
State Street Corp5,822,8404.63%$152.67M−473,3570.00%
Vanguard Capital Management LLC4,988,7563.97%$130.81M+117,2200.00%
Morgan Stanley4,451,0143.54%$116.71M+232,0830.01%
Jennison Associates LLC4,219,0583.36%$110.62M−761,7120.07%
D. E. Shaw & Co., Inc.3,949,6093.14%$103.56M+1,453,3870.05%
UBS Group AG3,333,0152.65%$87.39M+3,7910.01%
Bank Of America Corp /De/2,987,4312.38%$78.33M+766,1420.01%
Geode Capital Management, LLC2,982,4462.37%$78.21M−62,8600.00%
Vanguard Portfolio Management LLC2,429,0051.93%$63.69M+474,3200.00%
Orbimed Advisors LLC2,042,0001.62%$53.54MNew0.99%
Franklin Resources Inc1,930,9821.54%$50.63M−366,9610.01%
American Century Companies Inc1,925,0311.53%$50.47M+461,8030.02%
Goldman Sachs Group Inc1,668,3671.33%$43.74M+65,3540.00%
Jupiter Topco LLC1,410,4351.12%$36.99MNew0.02%
Oberweis Asset Management Inc/1,372,9411.09%$36.00M+7,0000.74%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026272131M100.0%42 / 95100 / 3618M18M
Q1 2026270133M100.0%41 / 10488 / 4821M10M
Q4 2025283129M100.0%74 / 10278 / 2520M17M
Q3 2025239126M100.0%34 / 8784 / 219M10M
Q2 2025230127M100.0%35 / 8967 / 4513M11M
Q1 2025241126M100.0%64 / 6780 / 298M11M
Q4 2024208129M100.0%49 / 6065 / 2815M16M
Q3 2024188130M100.0%34 / 7248 / 3120M10M
Q2 2024186128M100.0%47 / 5955 / 2921M27M
Q1 2024168134M100.0%59 / 5240 / 2343M16M
Q4 2023133107M85.5%40 / 5124 / 4060M20M
Q3 202313467M53.4%18 / 5338 / 183M6M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

213 funds held ARQT in Q2 2026, 50% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ARQTValue% of fundAs of
Vanguard Total Stock Market Index Fund3,564,9572.84%$93.47M0.00%Jun 30, 2026
iShares Russell 2000 ETF2,937,1922.34%$77.01M0.09%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2,914,1292.32%$76.41M0.71%Jun 30, 2026
Small Cap Growth Fund1,466,4111.17%$39.39M0.71%Jul 31, 2026
PGIM Jennison Small Company Fund1,386,2371.10%$36.35M1.04%Jun 30, 2026
Vanguard Extended Market Index Fund1,308,3121.04%$34.30M0.04%Jun 30, 2026
Fidelity Small Cap Index Fund1,250,5510.99%$33.59M0.10%Jul 31, 2026
Oberweis Small-Cap Opportunities Fund1,211,8000.96%$31.77M1.12%Jun 30, 2026
iShares Russell 2000 Growth ETF1,056,3180.84%$27.70M0.18%Jun 30, 2026
Baron Discovery Fund867,4000.69%$22.74M1.24%Jun 30, 2026
iShares Biotechnology ETF782,5950.62%$20.52M0.23%Jun 30, 2026
Fidelity Extended Market Index Fund576,4710.46%$12.37M0.03%May 31, 2026
Vanguard Russell 2000 Index Fund565,3570.45%$12.13M0.07%May 31, 2026
Vanguard Explorer Fund561,1830.45%$15.07M0.07%Jul 31, 2026
Schwab U.S. Small-Cap ETF534,0580.42%$11.46M0.05%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Todd WatanabeSee Remarks, Director895,1400.71%Nov 4, 2026
Patrick BurnettEVP, Chief Medical Officer116,6490.09%Nov 4, 2026
Robert LisickiEVP, Chief Commercial Officer55,0000.04%Nov 4, 2026
Masaru MatsudaEVP, Chief Legal Officer111,2890.09%Nov 4, 2026
Latha VairavanSVP Chief Financial Officer85,9780.07%May 13, 2026
Larry Todd EdwardsSee Remarks175,1780.14%Mar 3, 2026
David Joseph TopperChief Financial Officer182,7740.15%Apr 3, 2025
Robert A. ScottDirector20,3420.02%Nov 4, 2026
Howard G. WelgusDirector60,1980.05%Oct 19, 2026
Terrie CurranDirector23,5260.02%Aug 28, 2026
Christopher PeetzDirector191,8150.15%Jul 17, 2026
Sue-Jean LinDirector27,5670.02%Jun 17, 2026
Patrick J. HeronDirector59,6610.05%Jun 12, 2026
Keith R. LeonardDirector29,6510.02%Jun 9, 2026
Halley E. GilbertDirector27,9010.02%Jun 9, 2026
Neha KrishnamohanDirector27,9010.02%Jun 9, 2026
Amit MunshiDirector9,7990.01%Jun 9, 2026
Bhaskar ChaudhuriDirector917,8070.73%Jun 16, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Masaru Matsuda
EVP, Chief Legal Officer
Nov 4, 2026Sale(10b5-1 plan)−40,000$34.32$1.37M111,289
Masaru Matsuda
EVP, Chief Legal Officer
Nov 4, 2026Option exercise+40,000$3.64$145.60K151,289
Masaru Matsuda
EVP, Chief Legal Officer
Nov 2, 2026Sale(10b5-1 plan)−1,219$31.86$38.84K111,289
Patrick Burnett
EVP, Chief Medical Officer
Nov 2, 2026Sale−943$31.86$30.05K116,649
Todd Watanabe
See Remarks, Director
Nov 2, 2026Sale−4,377$31.86$139.47K712,826
Robert A. Scott
Director
Oct 23, 2026Award+2,819––2,819
Howard G. Welgus
Director
Oct 15, 2026Sale(10b5-1 plan)−4,728$26.93$127.33K35,207
Howard G. Welgus
Director
Oct 15, 2026Option exercise+2,254$8.63$19.45K39,935
Howard G. Welgus
Director
Oct 15, 2026Option exercise+1,018$7.51$7.65K37,681
Howard G. Welgus
Director
Oct 15, 2026Option exercise+822$6.52$5.36K36,663
Masaru Matsuda
See Remarks
Sep 16, 2026Sale(10b5-1 plan)−3,674$25.00$91.85K112,508
Howard G. Welgus
Director
Sep 15, 2026Option exercise+1,019$7.51$7.65K38,316
Howard G. Welgus
Director
Sep 15, 2026Option exercise+2,255$8.63$19.46K40,571
Howard G. Welgus
Director
Sep 15, 2026Sale(10b5-1 plan)−4,730$24.18$114.37K35,841
Howard G. Welgus
Director
Sep 15, 2026Option exercise+822$6.52$5.36K37,297
Masaru Matsuda
See Remarks
Sep 8, 2026Sale(10b5-1 plan)−9,989$25.03$250.02K116,182
Terrie Curran
Director
Aug 27, 2026Sale−27,052$25.03$677.11K23,526
Terrie Curran
Director
Aug 27, 2026Option exercise+11,148$7.51$83.72K34,674
Terrie Curran
Director
Aug 27, 2026Sale−11,148$25.03$279.03K23,526
Terrie Curran
Director
Aug 27, 2026Option exercise+27,052$8.63$233.46K50,578
Terrie Curran
Director
Aug 20, 2026Sale−1,072$26.04$27.91K23,526
Terrie Curran
Director
Aug 20, 2026Option exercise+1,072$7.51$8.05K24,598
Patrick Burnett
See Remarks
Aug 19, 2026Sale−1,697$27.00$45.82K117,592
Howard G. Welgus
Director
Aug 17, 2026Sale(10b5-1 plan)−4,730$26.18$123.83K36,475
Howard G. Welgus
Director
Aug 17, 2026Option exercise+822$6.52$5.36K37,931
Howard G. Welgus
Director
Aug 17, 2026Option exercise+1,019$7.51$7.65K38,950
Howard G. Welgus
Director
Aug 17, 2026Option exercise+2,255$8.63$19.46K41,205
Patrick Burnett
See Remarks
Aug 12, 2026Option exercise+6,700$3.64$24.39K125,989
Patrick Burnett
See Remarks
Aug 12, 2026Sale−6,700$26.08$174.74K119,289
Patrick Burnett
See Remarks
Aug 11, 2026Option exercise+8,300$3.64$30.21K127,589
Patrick Burnett
See Remarks
Aug 11, 2026Sale−8,300$26.52$220.12K119,289
Patrick Burnett
See Remarks
Aug 3, 2026Sale(10b5-1 plan)−955$26.12$24.94K119,289
Masaru Matsuda
See Remarks
Aug 3, 2026Sale(10b5-1 plan)−1,230$26.12$32.13K126,171
Todd Watanabe
See Remarks, Director
Aug 3, 2026Sale(10b5-1 plan)−4,375$26.12$114.28K717,203
Howard G. Welgus
Director
Jul 15, 2026Option exercise+822$6.52$5.36K38,565
Howard G. Welgus
Director
Jul 15, 2026Option exercise+1,019$7.51$7.65K39,584
Howard G. Welgus
Director
Jul 15, 2026Sale(10b5-1 plan)−4,730$26.91$127.28K37,109
Howard G. Welgus
Director
Jul 15, 2026Option exercise+2,255$8.63$19.46K41,839
Christopher Peetz
Director
Jul 15, 2026Award+4,315––4,315
Howard G. Welgus
Director
Jun 17, 2026Sale(10b5-1 plan)−635$25.67$16.30K37,743
Sue-Jean Lin
Director
Jun 15, 2026Sale(10b5-1 plan)−4,946$24.38$120.58K27,567
Howard G. Welgus
Director
Jun 15, 2026Sale(10b5-1 plan)−4,096$24.41$99.98K38,378
Howard G. Welgus
Director
Jun 15, 2026Option exercise+822$6.52$5.36K39,200
Howard G. Welgus
Director
Jun 15, 2026Option exercise+1,019$7.51$7.65K40,219
Howard G. Welgus
Director
Jun 15, 2026Option exercise+2,255$8.63$19.46K42,474
Terrie Curran
Director
Jun 5, 2026Award+5,778––23,526
Patrick J. Heron
Director
Jun 5, 2026Award+5,778––32,213
Howard G. Welgus
Director
Jun 5, 2026Award+5,778––38,378
Amit Munshi
Director
Jun 5, 2026Award+5,778––9,799
Keith R. Leonard
Director
Jun 5, 2026Award+5,778––27,901
Halley E. Gilbert
Director
Jun 5, 2026Award+5,778––27,901
Sue-Jean Lin
Director
Jun 5, 2026Award+5,778––32,513
Neha Krishnamohan
Director
Jun 5, 2026Award+5,778––27,901
Latha Vairavan
SVP Chief Financial Officer
May 11, 2026Sale(10b5-1 plan)−435$21.05$9.16K85,978
Patrick Burnett
See Remarks
May 11, 2026Sale(10b5-1 plan)−222$21.05$4.67K120,244
Patrick Burnett
See Remarks
May 4, 2026Sale(10b5-1 plan)−684$23.61$16.15K120,466
Latha Vairavan
SVP Chief Financial Officer
May 4, 2026Sale(10b5-1 plan)−1,341$23.61$31.66K86,413
Masaru Matsuda
See Remarks
May 4, 2026Sale(10b5-1 plan)−884$23.61$20.87K126,689
Masaru Matsuda
See Remarks
May 4, 2026Sale(10b5-1 plan)−7,372$23.27$171.55K127,573
Todd Watanabe
See Remarks, Director
May 4, 2026Sale(10b5-1 plan)−3,172$23.61$74.89K720,755

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
15.93%
18M shares short
Days to cover
7.6
At 2M shares a day
Change since last report
-11.4%
From 20M shares
Short volume, 20 days
58.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Arcutis Biotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 803 shares on Sep 3, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Masaru Matsuda
Officer
Nov 4, 202640,000$1.37MNov 4, 2026Stock Option Exercise
Todd Watanabe
Officer
Nov 2, 20264,377$139.47KNov 2, 2026Restricted Stock Vesting
Masaru Matsuda
Officer
Nov 2, 20261,219$38.84KNov 2, 2026Restricted Stock Vesting
Patrick Burnett
Officer
Nov 2, 2026943$30.05KNov 2, 2026Restricted Stock Vesting
Larry Todd Edwards
Former Officer
Oct 20, 202660,376$1.99MOct 20, 2026Employee Stock Purchase
Howard G. Welgus
Director
Oct 15, 20264,728$127.33KOct 15, 2026Restricted Stock Vesting
Larry Todd Edwards
Former Officer
Sep 16, 2026341,980$8.55MSep 16, 2026Stock Option Exercise
Howard G. Welgus
Director
Sep 15, 20264,730$114.37KSep 15, 2026Restricted Stock Vesting
Masaru Matsuda
Officer
Sep 8, 202613,663$341.93KSep 8, 2026Restricted Stock Vesting
Terrie Curran
Director
Aug 27, 202638,200$956.12KAug 27, 2026Stock Option Exercise
Terrie Curran
Director
Aug 20, 20261,072$27.91KAug 20, 2026Stock Option Exercise
Patrick Burnett
Officer
Aug 19, 20261,697$45.82KAug 19, 2026Restricted Stock Vest
Howard G. Welgus
Director
Aug 17, 20264,730$123.83KAug 17, 2026Restricted Stock Vesting
Patrick Burnett
Officer
Aug 11, 202615,000$397.82KAug 11, 2026Stock Option Exercise
Masaru Matsuda
Officer
Aug 3, 20261,230$32.12KAug 3, 2026Restricted Stock Vesting

Congress trades

6 trades in Arcutis Biotherapeutics reported by 2 members of the House

MemberTypeTradedAmountFiled
Gilbert Cisneros
CA31
BoughtMay 29, 2026$1K–15KJun 8, 2026
Gilbert Cisneros
CA31
BoughtMar 3, 2026$1K–15KApr 7, 2026
Gilbert Cisneros
CA31
Sold (part)Dec 11, 2025$1K–15KJan 12, 2026
Josh Gottheimer
NJ05 · joint account
SoldSep 15, 2023$1K–15KOct 15, 2023
Josh Gottheimer
NJ05 · joint account
BoughtApr 17, 2023$1K–15KMay 19, 2023
Josh Gottheimer
NJ05 · joint account
BoughtJun 15, 2022$1K–15KJul 22, 2022

See a number that looks wrong?